GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myeloma at ASCO. Adding ...

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.

Non-secretory myeloma is a rare form of myeloma. In people with this form, myeloma cells do not release an abnormal protein called paraprotein, making it harder to diagnose than other types of ...

SEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCLCoverage leverages new Medicare episode pricing ...

Hence, we’ll discuss Windows 11 multiple remote desktop sessions and how users can enable it. The RDP (Remote Desktop) is an operating system feature or software that allows users to connect and ...